Clovis And Avila Join In Oncology Drug/Diagnostic Deal
One year after securing startup financing, Clovis has acquired rights to a second program, this time Avila's EGFR mutant-selective inhibitor program.
One year after securing startup financing, Clovis has acquired rights to a second program, this time Avila's EGFR mutant-selective inhibitor program.